These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29444930)

  • 1. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
    Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
    Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
    [No Abstract]   [Full Text] [Related]  

  • 2. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
    Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
    Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients.
    Wang F; Cathcart SJ; DiMaio DJ; Zhao N; Chen J; Aizenberg MR; Shonka NA; Lin C; Zhang C
    J Neurooncol; 2022 Aug; 159(1):163-175. PubMed ID: 35754074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.
    Menard LC; Fischer P; Kakrecha B; Linsley PS; Wambre E; Liu MC; Rust BJ; Lee D; Penhallow B; Manjarrez Orduno N; Nadler SG
    Front Immunol; 2018; 9():2728. PubMed ID: 30534127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme.
    Lee M; Park C; Woo J; Kim J; Kho I; Nam DH; Park WY; Kim YS; Kong DS; Lee HW; Kim TJ
    Front Immunol; 2019; 10():555. PubMed ID: 30967876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
    Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
    Front Immunol; 2020; 11():835. PubMed ID: 32457755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging- and Tumor-Mediated Increase in CD8
    Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M
    Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
    Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
    Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Effector Phenotype of Tim-3
    Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
    Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
    [No Abstract]   [Full Text] [Related]  

  • 12. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
    Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
    Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
    Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
    Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
    Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
    Nakano M; Ito M; Tanaka R; Yamaguchi K; Ariyama H; Mitsugi K; Yoshihiro T; Ohmura H; Tsuruta N; Hanamura F; Sagara K; Okumura Y; Nio K; Tsuchihashi K; Arita S; Kusaba H; Akashi K; Baba E
    Cancer Sci; 2018 Sep; 109(9):2986-2992. PubMed ID: 30187676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR; Milne K; Nelson BH
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.